Shaigan Pharmaceuticals (Pvt) Ltd
Private pharmaceutical manufacturer · Rawalpindi · Pakistan
Rawalpindi-based pharmaceutical manufacturer focused on branded generic medicines, quality systems and international market expansion.
What is sourced, and how recent is it?
Regulatory-source portfolio data and company-supplied/corporate profile fields are tracked separately. Company claim/verification status is separate from source quality. An unclaimed company can still have a fully official-source-observed portfolio.
Company profile
- Legal / official name
- Shaigan Pharmaceuticals (Pvt.) Ltd.
- Company type
- Private pharmaceutical manufacturer
- Address
- 14-km, Adyala Road, Post Office Dahgal, Rawalpindi, Pakistan
- Website
- shaigan.com ↗
- Phone
- +92 51 5133060-8
- info@shaigan.com
- Official contact
- Contact page ↗
- Corporate source details checked
- 16 Aug 2026
- Corporate profile completeness
- 100%
Company location
A sourced company location is recorded. Use the map link below for directions.
Portfolio at a glance
RegistrationA unique regulatory registration number. One registration may have more than one strength/form/pack presentation.
PresentationA distinct medicine presentation, such as a particular strength, dosage form and pack.
IndexedA canonical MedInfoBase presentation that passed MedInfoBase identity and publication controls.
Source observedAn additional presentation observed in an official DRAP source but not counted as an indexed MedInfoBase presentation.
Registry onlyAn exact registry-verified registration not otherwise represented by an indexed or source-observed presentation.
Registry verifiedAn exact registration match found in an official DRAP registry source. This is evidence status, not a commercial ranking.
How complete is this profile?
Downloadable company intelligence charts
Copy or download any chart as a presentation-ready PNG. Every exported chart keeps MedInfoBase attribution and the source company-profile URL.
Therapeutic Portfolio Mix
Shows where the company portfolio is concentrated across broad therapeutic areas.
Portfolio distribution, not sales or market-share data.
Dosage Form Portfolio
Shows how the company portfolio is distributed across tablets, capsules, injections, liquids and other forms.
Counts are product presentations, not production or sales volumes.
Equivalent Price Position
Shows whether safely comparable products are below, near or above the peer median unit price.
This is price-position intelligence, not sales, demand or market-share data.
Closest Portfolio Competitors
Highlights other manufacturers with the greatest generic overlap with this company portfolio.
Competitor ranking is based on shared generics in MedInfoBase, not commercial sales performance.
Therapeutic areas
High-level clinical areas represented by this company’s current MedInfoBase portfolio.
Drug classes
More specific classes derived from the canonical generic and preserved curated classifications.
Dosage forms
How MedInfoBase classifies the portfolio
MedInfoBase uses a two-level taxonomy. Therapeutic area is a broad portfolio category, while drug class is the more specific pharmacological or clinical class. Existing curated classifications are preserved. Blank records are assigned conservatively from the canonical generic name and, when available, ATC information. Multi-use medicines may be placed in a cross-therapeutic category rather than forced into a single indication.
Deepest brand families
Unit-price positioning vs equivalent products
How MedInfoBase calculates price position
Only current prices with safely interpretable pack quantities are used. A product is compared only with the same generic, same stated strength, same dosage form and a compatible unit basis such as tablet, capsule, mL or gram. These are database-derived price comparisons, not sales or market-share estimates.
Portfolio overlap
Companies sharing the largest number of generics with this portfolio. This measures product overlap, not commercial performance.
Observed database signals
These dates describe records observed by MedInfoBase. They should not be interpreted as product launch dates or sales activity.
Medicine portfolio
This unified portfolio keeps three evidence lanes distinct: indexed MedInfoBase presentations, additional source-observed presentations, and registry-only registrations that are not otherwise represented. A registration number is not the same thing as a presentation, and source-observed rows are not counted as indexed. Source-only rows with a strength/form/pack contradiction remain visible as evidence but the conflicting field is held for normalization.
| Brand | Generic | Strength | Form | Pack | Registration | Source-listed price | Unit price | Price position |
|---|---|---|---|---|---|---|---|---|
| Emdagan Plus | Empagliflozin + Metformin | 12.5 mg + 1000 mg | Tablet | 14's | 110798 | PKR 720.02 | PKR 51.43/tablet | 15% below median |
| Emdagan Plus | Empagliflozin + Metformin | 5 mg + 500 mg | Tablet | 14's | 110799 | PKR 732.25 | PKR 52.30/tablet | 8% above median |
| Enaril | Enalapril | 5 mg | Tablet | 20's | 026641 | PKR 130.15 | PKR 6.51/tablet | 31% above median |
| Enaril | Enalapril | 10 mg | Tablet | 20's | 026642 | PKR 232.14 | PKR 11.61/tablet | 60% above median |
| Ergomin | Methylergometrine Maleate | 0.2 mg/mL | Injection | 50x1ml Amps. | 066614 | PKR 662.06 | — | No comparator |
| Fertab | Clomifene citrate | 50 mg | Tablet | 10's | 049131 | PKR 433.14 | PKR 43.31/tablet | Near median |
| FrenolSource observed | — | 400 mg/100 mL | IV infusion | 100ml | 135570Official source ↗ | No indexed price | — | — |
| Glykin | Amikacin | 500 mg | Injection | 2ml x1's | 054492 | PKR 262.33 | PKR 131.17/mL | 8% above median |
| Glykin | Amikacin | 250 mg | Injection | 2ml x1's | 054493 | PKR 140.76 | PKR 70.38/mL | 7% above median |
| Glykin | Amikacin | 100 mg | Injection | 2ml x1's | 054494 | PKR 87.44 | PKR 43.72/mL | Near median |
| Gravido | Oseltamivir | 75 mg | Capsule | 10's | 103368 | PKR 1,384.94 | PKR 138.49/capsule | 15% above median |
| Hygest | Hydroxyprogesterone caproate | 250 mg/mL | Injection | 1mlx3's | 094205 | PKR 281.43 | PKR 93.81/mL | No comparator |
| Hyvex | Hydroxychloroquine | 200 mg | Tablet | 30's | 084304 | PKR 556.15 | PKR 18.54/tablet | 28% above median |
| Iodino | Potassium iodide | 130 mg | Tablet | 20 | 101746 | PKR 45.02 | PKR 2.25/tablet | 16% below median |
| Iodino | Potassium iodide | 130 mg | Tablet | 28 | 101746 | PKR 41.59 | PKR 1.49/tablet | 45% below median |
| Iroton | Iron polymaltose complex | 50 mg/mL | Oral drops | 15ml | 041636 | PKR 140.55 | PKR 9.37/mL | 20% above median |
| Iroton | Iron | 50 mg/5 mL | Syrup | 90ml | 041637 | PKR 195.74 | PKR 2.17/mL | 9% below median |
| Iroton | Iron | 50 mg/5 mL | Syrup | 60ml | 041637 | PKR 151.36 | PKR 2.52/mL | Near median |
| Iroton Chewable | Elemental Iron | 100 mg | Chewable tablet | 2x10's | 052844 | PKR 367.58 | PKR 18.38/tablet | 24% above median |
| Iroton-F | Iron polymaltose complex + Folic acid | 100 mg elemental iron + 0.35 mg folic acid | Chewable tablet | 10's | 054495 | PKR 149.29 | PKR 14.93/tablet | 10% above median |
| Iroton-F | Iron polymaltose complex + Folic acid | 100 mg elemental iron + 0.35 mg folic acid | Chewable tablet | 100x10's | 054495 | PKR 12,608.51 | PKR 12.61/tablet | 11% below median |
| Isopreg | Dydrogesterone | 10 mg | Tablet | 2*10's | 082459 | PKR 808.01 | PKR 40.40/tablet | No comparator |
| Klolet | Clopidogrel | 75 mg | Tablet | 10's | 075098 | PKR 293.13 | PKR 29.31/tablet | 8% above median |
| Klolet | Clopidogrel + Aspirin | 75 mg + 75 mg | Tablet | 1x10's | 075401 | PKR 310.99 | PKR 31.10/tablet | 9% above median |
| Klolet | Clopidogrel + Aspirin | 75 mg + 150 mg | Tablet | 1x10's | 075402 | PKR 321.71 | PKR 32.17/tablet | 11% above median |
| L-ride | Lidocaine | 1 % | Injection | 2mlx50's | 045570 | PKR 183.34 | PKR 1.83/mL | 49% below median |
| Laclose | Lactulose | 3.35 g/5 mL | Syrup | 120ml | 024060 | PKR 305.67 | PKR 2.55/mL | 6% above median |
| Latmo Eye | Latanoprost | 50 mcg/mL | Ophthalmic drops | 2.5ml | 048976 | PKR 2,431.32 | PKR 972.53/mL | 98% above median |
| Melofen | Sulfadoxine + Pyrimethamine + Mefloquine | 500.0 mg + 25.0 mg + 274.0 mg | Tablet | 30's | 018667 | PKR 1,776.60 | PKR 59.22/tablet | No comparator |
| Melofin | Sulfadoxine + Pyrimethamine | 500 mg + 25 mg | Tablet | 3's | 025945 | PKR 19.19 | PKR 6.40/tablet | 32% below median |
| Melofin | Sulfadoxine + Pyrimethamine | 500 mg + 25 mg | Tablet | 10's | 025945 | PKR 81.04 | PKR 8.10/tablet | 14% below median |
| Mesan | Niclosamide | 500 mg | Tablet | 4's | 018668 | PKR 64.23 | PKR 16.06/tablet | No comparator |
| MetniSource observed | — | — | Tablet | 1x10's | 024059Official source ↗ | No indexed price | — | — |
| Metni TabletsSource observed | — | — | — | 1x10's | 024059Official source ↗ | No indexed price | — | — |
| Micasept Oral | Miconazole | 20 mg/g | Gel | 20gm | 081676 | PKR 180.18 | PKR 9.01/g | 7% above median |
| Micasept Topical | Miconazole | 20 mg/g | Cream | 20gm | 081677 | PKR 107.97 | PKR 5.40/g | 32% below median |
| Mionex | Moxifloxacin | 400 mg | Tablet | 5's | 049130 | PKR 994.58 | PKR 198.92/tablet | 8% above median |
| N-Glycrin SR | Nitroglycerin | 2.6 mg | Sustained-release tablet | 30's | 119088 | PKR 209.62 | PKR 6.99/tablet | 35% below median |
| Nisale | Sodium chloride | 0.9 % | Injection | 5mlx100's | 048091 | PKR 707.17 | PKR 1.41/mL | 67% above median |
| Nisale | Sodium chloride | 9 mg/mL | Injection | 5ml | 084354 | PKR 21.79 | PKR 4.36/mL | Near median |
| Rapaza | Ethinylestradiol | 0.02 mg | Tablet | 21's | 082460 | PKR 576.59 | PKR 27.46/tablet | No comparator |
| Remet-1.25 | Ramipril | 1.25 mg | Tablet | 14x2's | 057269 | PKR 493.18 | PKR 17.61/tablet | 15% above median |
| Remet-2.5 | Ramipril | 2.5 mg | Tablet | 14x2's | 057268 | PKR 863.07 | PKR 30.82/tablet | 19% above median |
| Remet-5 | Ramipril | 5 mg | Tablet | 14x2's | 057267 | PKR 986.38 | PKR 35.23/tablet | 11% above median |
| Riba | Ribavirin | 400 mg | Capsule | 10's | 038361 | PKR 681.55 | PKR 68.16/capsule | 19% above median |
| Riba-600 | Ribavirin | 600 mg | Capsule | 10's | 038362 | PKR 1,569.63 | PKR 156.96/capsule | 77% above median |
| Romycin | Clarithromycin | 250 mg | Tablet | 1x10's | 129739 | PKR 259.76 | PKR 25.98/tablet | 45% below median |
| Romycin | Clarithromycin | 500 mg | Tablet | 1x10's | 129740 | PKR 432.94 | PKR 43.29/tablet | 48% below median |
| Ruvar 200 | Lopinavir + Ritonavir | 200 mg + 50 mg | Tablet | 120's | 106253 | PKR 11,525.21 | PKR 96.04/tablet | Near median |
| Ruwin | Cefixime | 100 mg/5 mL | Suspension | 30 ml | 075354 | PKR 330.39 | PKR 11.01/mL | Near median |
MedInfoBase company-intelligence methodology
This page is generated from MedInfoBase medicine, generic, company, price and official-source records. Unverified third-party discovery records are retained internally for coverage auditing and are not published as company registrations. Portfolio leaders are ranked by presentation depth, not sales. Price-position metrics are calculated from current official-source prices normalized to compatible units and compared only against like-for-like products with the same generic, stated strength and dosage form.
Not currently included: sales volume, revenue by brand, market share, prescription volume or best-selling rankings. MedInfoBase will display those only when supported by a defensible licensed, public or company-verified source.
Cite this record
Manufacturer recordRecords change over time. Please cite the access date so readers can locate the version you used.